by Elena Iemma | Jan 22, 2025 | Blog
Regulatory T Cells and Immune Tolerance in Biologic Drug Development The recent Nobel Prize recognition of discoveries in immune tolerance highlights how far regulatory T cell biology has progressed, from foundational immunology to active therapeutic development....
by Elena Iemma | Sep 24, 2023 | Blog
Welcome to Tokyo! Yes, it’s true — EpiVax is in Japan for the Tokyo Immunogenicity Seminar! Sarah Moniz, Guilhem Richard (CTO of EpiVax Therapeutics), and I arrived Friday and have been exploring Tokyo landmarks all weekend. We’re thrilled to reconnect with friends...
by Elena Iemma | Aug 10, 2023 | News
PROVIDENCE, RI, August 10, 2023 /PRNewswire/ — EpiVax Inc. announces the publication of results from a research collaboration with the Food and Drug Administration aimed at streamlining generic drug evaluations. The research, initiated in 2018 with a $1M...
by Elena Iemma | Oct 17, 2022 | Events
We had a blast at AAPS PharmSci 360 in Boston! Thank you to everyone that attended our talks and poster sessions, and stopped by our booth or cocktail reception at Legal Seafoods! Pictures below! Talks: Anne De Groot, M.D., EpiVax, Inc. Deimmunization and Immune...
by Elena Iemma | Sep 12, 2022 | News
PROVIDENCE, RI, September 12, 2022 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) is pleased to announce the award of a two-year, $2 million grant from the FDA’s Office of Center for Drug Evaluation and Research (CDER) to validate a method for immunogenicity risk...
